In pre-market trading, shares are down 23% to $10.39.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NMRA:
- Neumora Therapeutics Announces Clinical Hold of Phase 1 NMRA-266 Study
- Neumora weakness amid lock-up expiration a buying opportunity, says RBC Capital
- Neumora Therapeutics to Participate at Stifel 2024 Virtual CNS Days
- Neumora Therapeutics price target raised to $31 from $24 at RBC Capital
- Neumora Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
Questions or Comments about the article? Write to editor@tipranks.com